BACKGROUND: Allergy has sharply increased in affluent Western countries in the last 30 years. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) may protect the immune system against development of allergy. METHODS: We prospectively categorized illnesses by body system in a subset of 91 children from the Kansas City cohort of the DIAMOND (DHA Intake and Measurement of Neural Development) study who had yearly medical records through 4 years of age. As infants, they were fed either a control formula without LCPUFA (n = 19) or one of three formulas with LCPUFA from docosahexaenoic acid (DHA) and arachidonic acid (ARA) (n = 72). RESULTS: Allergic illnesses in the first year were lower in the combined LCPUFA group compared to the control. LCPUFAs significantly delayed time to first allergic illness (p = 0.04) and skin allergic illness (p = 0.03) and resulted in a trend to reduced wheeze/asthma (p = 0.1). If the mother had no allergies, LCPUFAs reduced the risk of any allergic diseases (HR = 0.24, 95% CI = 0.1, 0.56, p = 0.0.001) and skin allergic diseases (HR = 0.35, 95% CI = 0.13, 0.93, p = 0.04). In contrast, if the mother had allergies, LCPUFAs reduced wheezing/asthma (HR = 0.26, 95% CI = 0.07, 0.9, p = 0.02). CONCLUSIONS: LCPUFA supplementation during infancy reduced the risk of skin and respiratory allergic diseases in childhood with effects influenced by maternal allergies.
BACKGROUND:Allergy has sharply increased in affluent Western countries in the last 30 years. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) may protect the immune system against development of allergy. METHODS: We prospectively categorized illnesses by body system in a subset of 91 children from the Kansas City cohort of the DIAMOND (DHA Intake and Measurement of Neural Development) study who had yearly medical records through 4 years of age. As infants, they were fed either a control formula without LCPUFA (n = 19) or one of three formulas with LCPUFA from docosahexaenoic acid (DHA) and arachidonic acid (ARA) (n = 72). RESULTS:Allergic illnesses in the first year were lower in the combined LCPUFA group compared to the control. LCPUFAs significantly delayed time to first allergic illness (p = 0.04) and skin allergic illness (p = 0.03) and resulted in a trend to reduced wheeze/asthma (p = 0.1). If the mother had no allergies, LCPUFAs reduced the risk of any allergic diseases (HR = 0.24, 95% CI = 0.1, 0.56, p = 0.0.001) and skin allergic diseases (HR = 0.35, 95% CI = 0.13, 0.93, p = 0.04). In contrast, if the mother had allergies, LCPUFAs reduced wheezing/asthma (HR = 0.26, 95% CI = 0.07, 0.9, p = 0.02). CONCLUSIONS: LCPUFA supplementation during infancy reduced the risk of skin and respiratory allergic diseases in childhood with effects influenced by maternal allergies.
Authors: N D'Vaz; S J Meldrum; J A Dunstan; T F Lee-Pullen; J Metcalfe; B J Holt; M Serralha; M K Tulic; T A Mori; S L Prescott Journal: Clin Exp Allergy Date: 2012-08 Impact factor: 5.018
Authors: Tanya L Blasbalg; Joseph R Hibbeln; Christopher E Ramsden; Sharon F Majchrzak; Robert R Rawlings Journal: Am J Clin Nutr Date: 2011-03-02 Impact factor: 7.045
Authors: Eileen E Birch; Susan E Carlson; Dennis R Hoffman; Kathleen M Fitzgerald-Gustafson; Valeria L N Fu; James R Drover; Yolanda S Castañeda; Laura Minns; Dianna K H Wheaton; David Mundy; John Marunycz; Deborah A Diersen-Schade Journal: Am J Clin Nutr Date: 2010-02-03 Impact factor: 7.045
Authors: N D'Vaz; S J Meldrum; J A Dunstan; D Martino; S McCarthy; J Metcalfe; M K Tulic; T A Mori; S L Prescott Journal: Pediatrics Date: 2012-09-03 Impact factor: 7.124
Authors: Kathleen Lee-Sarwar; Rachel S Kelly; Jessica Lasky-Su; Priyadarshini Kachroo; Robert S Zeiger; George T O'Connor; Megan T Sandel; Leonard B Bacharier; Avraham Beigelman; Nancy Laranjo; Diane R Gold; Scott T Weiss; Augusto A Litonjua Journal: J Allergy Clin Immunol Pract Date: 2018-08-24
Authors: Tamara Hoppenbrouwers; Jelena H Cvejić Hogervorst; Johan Garssen; Harry J Wichers; Linette E M Willemsen Journal: Front Immunol Date: 2019-05-22 Impact factor: 7.561